<DOC>
	<DOCNO>NCT01987492</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled , parallel-group study evaluate efficacy lebrikizumab compare placebo , measure ability participant achieve low daily dos OCS , among severe corticosteroid-dependent asthma . Prednisone/prednisolone OCS therapy prescribed . Participants randomize receive lebrikizumab match placebo 44 week double-blind , placebo-controlled ( DBPC ) period . Those complete 44-week period may continue 32-week active treatment extension ( ATE ) period , participant receive lebrikizumab treatment . Following completion ATE period , participant tolerate derived benefit treatment lebrikizumab may continue lebrikizumab treatment long-term extension ( LTE ) period . Participants transition 24 week safety follow-up upon discontinuation study drug .</brief_summary>
	<brief_title>A Study Lebrikizumab ( RO5490255 ) Participants With Severe Oral Corticosteroids ( OCS ) Dependent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Severe asthma despite intensive followup asthma specialist &gt; /=6 month prior Visit 1 Baseline force expiratory volume 1 second ( FEV1 ) &gt; /=40 % predict prior randomization Receiving high dos inhale glucocorticosteroids total daily dose &gt; /=1500 microgram ( mcg ) beclomethasone dipropionate equivalent longacting betaadrenoceptor agonist ( LABA ) , without additional controller , least 3 month prior Visit 1 Chronic treatment maintenance OCS &gt; /=6 month prior Visit 1 Assessment ensure diagnosis refractory asthma OCS dependence minimal effective maximum tolerate dose prior Visit 1 compliance History severe allergic reaction anaphylactic reaction biologic agent know hypersensitivity component lebrikizumab injection Asthma exacerbation within 28 day prior Visit 1 screening ( prior Visit 3 ) For adult : Active tuberculosis require treatment within 12 month prior Visit 1 For adolescent : History active tuberculosis require treatment Evidence acute chronic hepatitis know liver cirrhosis Known current malignancy current evaluation potential malignancy History interstitial lung disease , chronic obstructive pulmonary disease , clinically significant lung disease asthma Infection require hospital admission require treatment intravenous ( IV ) intramuscular ( IM ) antibiotic within 4 week prior Visit 1 screen Upper low respiratory tract infection within 4 week prior Visit 1 screen Active parasitic infection Listeria monocytogenes infection within 6 month prior Visit 1 screen Current smoker former smoker smoke history 15 packyears Current use immunomodulatory/ immunosuppressive therapy past use within 3 month 5 drug halflives ( whichever longer ) prior Visit 1 Use license investigational monoclonal antibody antiinterleukin ( IL ) 13 antiIL4/IL13 , include limited , omalizumab , antiIL5 , antiIL17 , within 6 month 5 drug halflives ( whichever longer ) prior Visit 1 Receipt live attenuate vaccine within 4 week prior Visit 1 screen anticipation receipt live attenuate vaccine throughout study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>